Inhalation Sciences to present findings of PreciseInhale clinical study at DDL 2022
(Stockholm 20 September 2022) ISAB’s conference paper on its study validating PreciseInhale[®] for clinical use has been accepted by the Drug Delivery to the Lungs (DDL) conference 2022 - one of the inhalation markets’ most influential events. The study demonstrates that PreciseInhale[®] outperformed standard commercial inhalers and improved ‘regional targeting’ of aerosols to specific areas of the lungs. The data will be presented as a Poster at the event.DDL 2022 (7- 9 December, Edinburgh, Scotland) will be a particularly important event as it will be the first to be held entirely onsite